rns® system Search Results


fam20c antibody  (Proteintech)
93
Proteintech fam20c antibody
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Fam20c Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/FAM20C+Antibody/pmc11231076-176-19-25
Average 93 stars, based on 1 article reviews
fam20c antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
sodium chloride  (Chem Impex International)
95
Chem Impex International sodium chloride
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Sodium Chloride, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/Sodium+chloride/10__3390_slash_molecules30112371-160-26-29
Average 95 stars, based on 1 article reviews
sodium chloride - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
sodium fluoride  (Chem Impex International)
95
Chem Impex International sodium fluoride
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Sodium Fluoride, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/Sodium+fluoride/bio_rxiv__2024__06__05__597552-145-64-66
Average 95 stars, based on 1 article reviews
sodium fluoride - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
rns  (Garmin Ltd)
86
Garmin Ltd rns
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Rns, supplied by Garmin Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/rns/pmc13136088-109-5-8
Average 86 stars, based on 1 article reviews
rns - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
responsive neural stimulator rns  (NeuroPace)
90
NeuroPace responsive neural stimulator rns
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Responsive Neural Stimulator Rns, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/responsive+neural+stimulator+rns/pm33926248-7-3-7
Average 90 stars, based on 1 article reviews
responsive neural stimulator rns - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
resection plus responsive neurostimulation rns  (NeuroPace)
90
NeuroPace resection plus responsive neurostimulation rns
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Resection Plus Responsive Neurostimulation Rns, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/rns+tm++responsive+neurostimulation+system+epilepsy/pmc07658333-32-9-14
Average 90 stars, based on 1 article reviews
resection plus responsive neurostimulation rns - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
responsive neurostimulation rns  (NeuroPace)
90
NeuroPace responsive neurostimulation rns
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Responsive Neurostimulation Rns, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/responsive+neurostimulation+rns/pmc09418593-138-6-9
Average 90 stars, based on 1 article reviews
responsive neurostimulation rns - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rns device  (NeuroPace)
90
NeuroPace rns device
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Rns Device, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/rns+device/pm39353259-245-3-3
Average 90 stars, based on 1 article reviews
rns device - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rns system  (NeuroPace)
90
NeuroPace rns system
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Rns System, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/rns+system/pm38639704-211-28-15
Average 90 stars, based on 1 article reviews
rns system - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rns device neuropace rns  (NeuroPace)
90
NeuroPace rns device neuropace rns
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Rns Device Neuropace Rns, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/neuropace+rns+system/pmc10733995-205-7-9
Average 90 stars, based on 1 article reviews
rns device neuropace rns - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
closed-loop responsive neurostimulation (rns) system  (NeuroPace)
90
NeuroPace closed-loop responsive neurostimulation (rns) system
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Closed Loop Responsive Neurostimulation (Rns) System, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/closed+loop+responsive+neurostimulation++rns++system/10__3171_slash_2020__5__peds20118-1-74-79
Average 90 stars, based on 1 article reviews
closed-loop responsive neurostimulation (rns) system - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
programmable biomarker detector neurostimulator model rns-300  (NeuroPace)
90
NeuroPace programmable biomarker detector neurostimulator model rns-300
Expression Levels of FAM20A and <t>FAM20C</t> in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.
Programmable Biomarker Detector Neurostimulator Model Rns 300, supplied by NeuroPace, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rns%C2%AE+system/rns+300m/pmc05776799__pnas__201712214SI-43-9-15
Average 90 stars, based on 1 article reviews
programmable biomarker detector neurostimulator model rns-300 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Expression Levels of FAM20A and FAM20C in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Expression Levels of FAM20A and FAM20C in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.

Article Snippet: After blocking with 5% BSA, the membrane was incubated with polyclonal anti-FAM20A (1:1000, Cat. No. 25258–1-AP, Proteintech, USA), and FAM20C antibody (1:1,000, Cat. No. 25395–1-AP, Proteintech, USA) in a primary antibody dilution buffer (Epizyme, China).

Techniques: Expressing, Derivative Assay, Comparison, Quantitative Proteomics, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Sequencing

Survival Analysis in LUSC Based on FAM20A and FAM20C. Utilizing the GEPIA2 tool, overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in LUSC were analyzed in relation to the expression of FAM20A and FAM20C, with survival plots provided. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; FAM20C, Family with Sequence Similarity 20, Member C; GEPIA2, Gene Expression Profiling Interactive Analysis 2; OS, Overall survival; DSS, Disease-specific survival; PFI, Progression-free interval.

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Survival Analysis in LUSC Based on FAM20A and FAM20C. Utilizing the GEPIA2 tool, overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in LUSC were analyzed in relation to the expression of FAM20A and FAM20C, with survival plots provided. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; FAM20C, Family with Sequence Similarity 20, Member C; GEPIA2, Gene Expression Profiling Interactive Analysis 2; OS, Overall survival; DSS, Disease-specific survival; PFI, Progression-free interval.

Article Snippet: After blocking with 5% BSA, the membrane was incubated with polyclonal anti-FAM20A (1:1000, Cat. No. 25258–1-AP, Proteintech, USA), and FAM20C antibody (1:1,000, Cat. No. 25395–1-AP, Proteintech, USA) in a primary antibody dilution buffer (Epizyme, China).

Techniques: Expressing, Sequencing, Gene Expression

Association of FAM20A and FAM20C levels with Clinical Pathological Traits in LUSC. (A) Overall survival, (B) Disease specific survival and (C) Progress Free interval of FAM20A mRNA levels. (D) Overall survival, (E) Disease specific survival and (F) Progress Free interval of FAM20C mRNA levels. Significant levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Squance Similarity 20, member A; Fam20C, Family with Squance Similarity 20, member C.

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Association of FAM20A and FAM20C levels with Clinical Pathological Traits in LUSC. (A) Overall survival, (B) Disease specific survival and (C) Progress Free interval of FAM20A mRNA levels. (D) Overall survival, (E) Disease specific survival and (F) Progress Free interval of FAM20C mRNA levels. Significant levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Squance Similarity 20, member A; Fam20C, Family with Squance Similarity 20, member C.

Article Snippet: After blocking with 5% BSA, the membrane was incubated with polyclonal anti-FAM20A (1:1000, Cat. No. 25258–1-AP, Proteintech, USA), and FAM20C antibody (1:1,000, Cat. No. 25395–1-AP, Proteintech, USA) in a primary antibody dilution buffer (Epizyme, China).

Techniques: